---
title: "NG-TEST Acineto-5 accurately detects OXA, NDM, and VIM carbapenemases in Acinetobacter spp."
id: "medrxiv-5-validation-of-ng-test-acineto-5-for-the-detection-of-oxa-carbapenemases-ndm-and"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-5-validation-of-ng-test-acineto-5-for-the-detection-of-oxa-carbapenemases-ndm-and"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.10.19.26365660v1?rss=1"
published_at: "2026-10-23T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# NG-TEST Acineto-5 accurately detects OXA, NDM, and VIM carbapenemases in Acinetobacter spp.
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-5-validation-of-ng-test-acineto-5-for-the-detection-of-oxa-carbapenemases-ndm-and
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.10.19.26365660v1?rss=1)
- **Published At:** 2026-10-23T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The study evaluated **NG-TEST Acineto-5**, a lateral flow immunoassay, for rapid detection of major acquired carbapenemases in Acinetobacter species. - Investigators tested 433 whole-genome-sequenced isolates; the collection included predominantly **Acinetobacter baumannii** (n = 365) and **Acinetobacter pittii** (n = 33), plus 13 other species represented by 1–7 isolates each. - The isolate panel contained single producers of OXA-23-like (n = 126), OXA-24-like (n = 14), OXA-58-like (n = 8), OXA-143/253/542 (n = 10), VIM-like (n = 9), and **NDM-like** enzymes (n = 25). - Co-producers were present: 20 isolates carried two carbapenemases and 2 isolates carried three carbapenemases; all tested variants and combinations were included. - The assay detected every targeted carbapenemase in the panel, yielding reported sensitivity of 100% across tested enzymes and combinations, according to the authors. - No false positives occurred among isolates lacking the targeted carbapenemases; the authors reported 100% specificity in that cohort. - Cross-reactivity was observed: OXA-24-like, OXA-143-like, and OXA-542 were detected by the same antibody pair, demonstrating intra-group recognition. - Weak positive signals appeared in four of five A. radioresistens isolates that carry intrinsic blaOXA-23-like genes, consistent with low-level expression noted by the investigators. - Authors argue **NDM** and **VIM** detection is clinically relevant because these enzymes are not inhibited by durlobactam and have been linked to increased cefiderocol MICs, potentially reducing treatment options. - The preprint declares potential competing interests: several authors are NG Biotech employees and supplied test kits; data analysis was performed by investigators not involved in kit development and independently reviewed, as reported. - The manuscript contains all study data; the preprint has not been peer-reviewed and the authors state it should not be used to guide clinical practice.
## Clinical Analysis & Structured Key Points
[Skip to main content](https://www.medrxiv.org/content/10.64898/2026.10.19.26365660v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Validation of NG-TEST Acineto-5 for the Detection of OXA Carbapenemases, NDM, and VIM in the Acinetobacter calcoaceticus-baumannii Complex and beyond [ View ORCID Profile](http://orcid.org/0000-0001-5766-3831)Saoussen Oueslati, Alphee PIARD, Arnaud CHALIN, Laura Francius, Anais VOGEL, Margaux LE QUELLEC, Emeric DUPRE, Christian MOGUET, [ View ORCID Profile](http://orcid.org/0000-0002-6071-8255)Stephanie Simon, Herve VOLLAND, [ View ORCID Profile](http://orcid.org/0000-0002-4634-8550)Katy Jeannot, [ View ORCID Profile](http://orcid.org/0000-0001-9937-9572)Thierry Naas doi: https://doi.org/10.64898/2026.10.19.26365660 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Saoussen Oueslati 1 Universite Paris-Saclay CentraleSupelec; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Saoussen%2BOueslati%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Oueslati%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASaoussen%2BOueslati%2B) * [ORCID record for Saoussen Oueslati](http://orcid.org/0000-0001-5766-3831 "Open in new tab") Alphee PIARD 2 CNR de la Resistance aux Antibiotiques; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Alphee%2BPIARD%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=PIARD%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAlphee%2BPIARD%2B) Arnaud CHALIN 3 NG Biotech; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Arnaud%2BCHALIN%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=CHALIN%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AArnaud%2BCHALIN%2B) Laura Francius 3 NG Biotech; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Laura%2BFrancius%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Francius%20L&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ALaura%2BFrancius%2B) Anais VOGEL 4 CEA Gif/Yvette; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Anais%2BVOGEL%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=VOGEL%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAnais%2BVOGEL%2B) Margaux LE QUELLEC 5 NG Biotech (France); * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Margaux%2BLE%2BQUELLEC%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=QUELLEC%20ML&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMargaux%2BLE%2BQUELLEC%2B) Emeric DUPRE 6 Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé, Gif-sur-Yvette; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Emeric%2BDUPRE%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=DUPRE%20E&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AEmeric%2BDUPRE%2B) Christian MOGUET 7 CEA, Gif/Yvette; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Christian%2BMOGUET%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=MOGUET%20C&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AChristian%2BMOGUET%2B) Stephanie Simon 8 CEA Saclay; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Stephanie%2BSimon%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Simon%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AStephanie%2BSimon%2B) * [ORCID record for Stephanie Simon](http://orcid.org/0000-0002-6071-8255 "Open in new tab") Herve VOLLAND 9 Service de Pharmacologie et Immuno-analyse (SPI), JOLIOT, CEA, INRA, Université Paris-Saclay; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Herve%2BVOLLAND%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=VOLLAND%20H&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AHerve%2BVOLLAND%2B) Katy Jeannot 10 Centre hospitalier regional universitaire de Besancon; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Katy%2BJeannot%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Jeannot%20K&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKaty%2BJeannot%2B) * [ORCID record for Katy Jeannot](http://orcid.org/0000-0002-4634-8550 "Open in new tab") Thierry Naas 11 Assistance Publique - Hopitaux de Paris Universite Paris Saclay * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Thierry%2BNaas%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Naas%20T&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AThierry%2BNaas%2B) * [ORCID record for Thierry Naas](http://orcid.org/0000-0001-9937-9572 "Open in new tab") * For correspondence: thierry.naas@aphp.fr * [Abstract](https://www.medrxiv.org/content/10.64898/2026.10.19.26365660v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1328576/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.10.19.26365660v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1328576/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.10.19.26365660v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1328576/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.10.19.26365660v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1328576/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.10.19.26365660v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1328576/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Carbapenem resistance in Acinetobacter spp. is frequently mediated by acquired carbapenemases, whose rapid detection can inform antimicrobial therapy and infection-control decisions. NG-TEST Acineto-5 is a lateral flow immunoassay designed to detect major acquired carbapenemases in Acinetobacter spp. We evaluated its performance using 433 whole-genome-sequenced isolates, including single producers of OXA-23-like (n = 126), OXA-24-like (n = 14), OXA-58-like (n = 8), OXA-143/253/542 (n = 10), VIM-like (n = 9), and NDM-like enzymes (n = 25), as well as isolates co-producing two (n = 20) or three (n = 2) carbapenemases. The collection was predominantly composed of Acinetobacter baumannii (n = 365) and Acinetobacter pittii (n = 33), with 13 additional species represented by 1 to 7 isolates each. The assay detected all targeted carbapenemases, including all tested variants and combinations, yielding 100% sensitivity. OXA-24-like, OXA-143-like, and the distantly related OXA-542 were detected by the same antibody pair, demonstrating cross-reactivity within this group. No false-positive results occurred among isolates lacking targeted carbapenemases, resulting in 100% specificity. Weak positive signals were observed in four of five A. radioresistens isolates carrying intrinsic blaOXA-23-like genes, consistent with low-level expression. Overall, NG-TEST Acineto-5 enables rapid detection of major acquired carbapenemases in Acinetobacter spp., supporting infection control, epidemiological surveillance and therapeutic decision-making, as carbapenemase-producing isolates are often multidrug resistant. Detection of VIM and NDM may be particularly valuable because these enzymes are not inhibited by durlobactam and have been associated with increased cefiderocol MICs, potentially limiting treatment options. ### Competing Interest Statement A.C., L.F., M.L.Q., and C.M. are employees of NG Biotech and were involved in the development of the NG-TEST Acineto-5 evaluated in this study. NG-TEST Acineto-5 were provided free of charge by NG Biotech. NG Biotech was not involved in experimental evaluation, data analysis, interpretation of the results, or preparation of the manuscript. Data analysis and interpretation were performed by investigators not involved in the development of the evaluated kit and were independently reviewed by two researchers from each investigator team. All other authors declare no conflicts of interest related to this work. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: All the isolates have been de-identified I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability All data produced in the present work are contained in the manuscript Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.10.19.26365660v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.10.20.26366069v1 ""They could just come, they peep, then they get back": COVID-19 patients' experiences of care in isolation in Nairobi, Kenya")[Next ](https://www.medrxiv.org/content/10.64898/2026.10.21.26365944v1 "A Data-Driven Pediatric Type 1 Diabetes Population Health Model Within Specialty Value-Based Care") Posted October 23, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.10.19.26365660v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/10/23/2026.10.19.26365660.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.10.19.26365660v1#p-5) [ Data/Code](https://www.medrxiv.org/content/early/2026/10/23/2026.10.19.26365660.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Validation of NG-TEST Acineto-5 for the Detection of OXA Carbapenemases, NDM, and VIM in the Acinetobacter calcoaceticus-baumannii Complex and beyond Saoussen Oueslati, Alphee PIARD, Arnaud CHALIN, Laura Francius, Anais VOGEL, Margaux LE QUELLEC, Emeric DUPRE, Christian MOGUET, Stephanie Simon, Herve VOLLAND, Katy Jeannot, Thierry Naas medRxiv 2026.10.19.26365660; doi: https://doi.org/10.64898/2026.10.19.26365660 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.10.19.26365660v1%26text%3DValidation%2520of%2520NG-TEST%2520Acineto-5%2520for%2520the%2520Detection%2520of%2520OXA%2520Carbapenemases%252C%2520NDM%252C%2520and%2520VIM%2520in%2520the%2520Acinetobacter%2520calcoaceticus-baumannii%2520Complex%2520and%2520beyond "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.10.19.26365660v1%26t%3DValidation%2520of%2520NG-TEST%2520Acineto-5%2520for%2520the%2520Detection%2520of%2520OXA%2520Carbapenemases%252C%2520NDM%252C%2520and%2520VIM%2520in%2520the%2520Acinetobacter%2520calcoaceticus-baumannii%2520Complex%2520and%2520beyond "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.10.19.26365660v1%26title%3DValidation%2520of%2520NG-TEST%2520Acineto-5%2520for%2520the%2520Detection%2520of%2520OXA%2520Carbapenemases%252C%2520NDM%252C%2520and%2520VIM%2520in%2520the%2520Acinetobacter%2520calcoaceticus-baumannii%2520Complex%2520and%2520beyond%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.10.19.26365660v1%26title%3DValidation%2520of%2520NG-TEST%2520Acineto-5%2520for%2520the%2520Detection%2520of%2520OXA%2520Carbapenemases%252C%2520NDM%252C%2520and%2520VIM%2520in%2520the%2520Acinetobacter%2520calcoaceticus-baumannii%2520Complex%2520and%2520beyond "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.10.19.26365660) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.10.19.26365660v1&count=horizontal&via=&text=Validation%20of%20NG-TEST%20Acineto-5%20for%20the%20Detection%20of%20OXA%20Carbapenemases%2C%20NDM%2C%20and%20VIM%20in%20the%20Acinetobacter%20calcoaceticus-baumannii%20Complex%20and%20beyond&counturl=www.medrxiv.org/content/10.64898/2026.10.19.26365660v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (634) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (914) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (347) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4944) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (490) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (425) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (672) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1667) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (16164) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (36) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1236) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (7214) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (747) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1091) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (5225) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1456) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1813) * [Hematology](https://www.medrxiv.org/collection/hematology) (597) * [HIV/AIDS](https:
## Related Clinical Research

- [8-hour time-restricted eating yields greater weight loss but not consistent blood pressure benefits](https://medichelpline.com/clinical-feed/medical-news-today-0-16-8-intermittent-fasting-best-for-weight-loss-but-not-for-blood-pressure.md)
- [Efgartigimod for refractory thymoma-associated overlap of stiff-person syndrome and myasthenia gra](https://medichelpline.com/clinical-feed/frontiers-in-immunology-3-case-report-efgartigimod-a-beacon-of-hope-for-overlapping-stiff-person-syndrome.md)
- [Remembering Helen Branswell — STAT’s Infectious-Disease Reporter](https://medichelpline.com/clinical-feed/stat-news-3-remembering-stat-s-helen-branswell.md)
- [Patient accounts from Nairobi show fear-driven distancing in COVID-19 isolation care](https://medichelpline.com/clinical-feed/medrxiv-2-they-could-just-come-they-peep-then-they-get-back-covid-19-patients-experiences.md)
- [Choosing spatial aggregation scale in epidemic models: compression versus distortion](https://medichelpline.com/clinical-feed/medrxiv-19-choosing-the-spatial-scale-of-aggregation-in-epidemic-models-compression-versus.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.